Up to half of patients receiving chemotherapy of moderate or high emetic risk experience CINV despite optimal anti-emetic prophylaxis1. Limited evidence suggests cannabinoid medicine in the form of tetrahydrocannabinol (THC) may reduce CINV, and addition of cannabidiol (CBD) may improve efficacy and tolerance. The aim of this multi-centre, randomised, placebo-controlled, phase II/III trial is to determine efficacy of addition of an oral cannabinoid-rich THC/CBD cannabis extract for control of CINV.
Target population is adult patients experiencing CINV during moderate and highly emetogenic chemotherapy regimens despite appropriate anti-emetic therapy, who are scheduled to receive at least 2 more consecutive cycles (A, B and, where applicable, C). Treatment consists of oral THC 2.5mg/CBD 2.5mg (Tilray TN-TC11M) capsules or placebo TDS days -1 to 5, in addition to guideline-consistent anti-emetics, including rescue medications. In the pilot trial (N=80), subjects are randomised for cycle A, cross-over for cycle B, and nominate preferred treatment for cycle C. In the planned definitive trial (N=250), subjects are randomised to investigational product or placebo for cycles A, B and C in a parallel design. The primary end-point is the proportion of patients gaining a complete response (no emesis and no use of rescue medications) (0 – 120h), with additional end-points of (i) complete response, (ii) no emesis, (iii) no significant nausea and (iv) no use of rescue medication during the a) acute, b) delayed, and c) overall phases of cycle A, B and C, (iv) adverse events, (v) quality of life, and (vi) health economics.
Pilot trial in progress: 10 NSW sites open, 22 of 80 patients recruited. Expected recruitment completion is April 2018.
Funding: NSW Department of Health.
Acknowledgements: Trial participants, investigators and research staff. Drug supply by Tilray.